{"url_path":"/sec/bngo/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000027-index.html","accession_number":"0001411690-26-000027","cik":"0001411690","ticker":"BNGO","issuer_name":"Bionano Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000027-index.html","primary_entity_key":"0001411690","primary_entity_name":"Bionano Genomics, Inc."},"word_count":95,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit No.\n\n \n\nDescription\n\n99.1\n\n \n\n[Press release issued May 13, 2026, reporting financial results for the first quarter ended March 31, 2026](bngo-ex99_1.htm)\n\n104\n\n \n\nInline XBRL for the cover page of this Current Report on Form 8-K\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nBionano Genomics, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Albert A. Luderer, Ph.D.\n\n \n\n \n\nAlbert A. Luderer, Ph.D.\n\n \n\n \n\nInterim Chief Executive Officer"}